Targeted surveillance strategies for efficient detection of novel antibiotic resistance variants
- Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States
- Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Australia
- Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, United States
- Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, United States
Figures
Figure 1 with 1 supplement
The impact of demography-, niche-, and geography-aware sampling on the detection efficiency of genetic resistance variants.
Dot plots showing the detection efficiency (with lines indicating the mean and 95% confidence intervals from 100 simulations) for resistance variants RplD G70D (A–B), 23S rRNA C2611T (C–D), and penA …
Figure 1—figure supplement 1
Isolates from patients with travel-associated gonorrhea are associated with longer terminal branches compared to patients with locally-acquired gonorrhea.
Maximum-likelihood phylogeny produced from the pseudogenome alignment (with predicted regions of recombination removed) of isolates from dataset 2 (A). Patient travel history is indicated by the …
Figure 2 with 1 supplement
The impact of phylogeny-aware sampling on the detection efficiency of genetic resistance and diagnostic escape variants.
Scatter dot plots showing the detection efficiency (with lines indicating the mean and 95% confidence intervals from 100 simulations) for resistance variants RplD G70D (A), 23S rRNA C2611T (B), and p…
Figure 2—figure supplement 1
Detection efficiency of clonal group sampling across different similarity thresholds.
Scatter dot plots showing the detection efficiency (with lines indicating the mean and 95% confidence intervals from 100 simulations) for resistance variants RplD G70D (A), 23S rRNA C2611T (B), and p…
Figure 3
The impact of genomic background-aware sampling on the detection efficiency of phenotypic resistance variants.
Bar charts showing the proportions of ceftriaxone reduced susceptibility (CRO-RS) isolates, ceftriaxone susceptible (CRO-S) isolates, cefixime resistant (CFX-R) isolates, and cefixime susceptible …
Tables
Table 1
Summary of datasets.
| Dataset | Temporal range | Nisolates | Geographic range | Metadata available | SRA study ID/Reference |
|---|---|---|---|---|---|
| 1 | 2011–2015 | 896 | New York, NY, US | Gender, sexual behavior, anatomical site of isolation | ERP011192 (Mortimer et al., 2020) |
| 2 | 2016–2017 | 2186 | Victoria, Australia | Gender, sexual behavior, anatomical site of isolation, travel history, sex worker status | SRP185594 (Williamson et al., 2019) |
| 3 | 2013 | 1054 | Europe | Country of sample collection | ERP010312 (Harris et al., 2018) |
| 4 | 2015 | 244 | Japan | Prefecture of sample collection | DRP004052 (Yahara et al., 2018) |
| 5 | 2014–2015 | 398 | New Zealand | N/A | SRP111927 (Lee et al., 2018b) |
Table 2
Summary by dataset of the prevalence and distribution of the genetic markers of resistance and resistance phenotypes tested.
| Variant | Genetic | Phenotypic | ||||
|---|---|---|---|---|---|---|
| RplD G70D | 23S rRNA C2611T (2–4 alleles) | penA XXXIV | CRO-RS (≥0.12 μg/mL) | CFX-R (>0.25 μg/mL) | ||
| Drug | AZM (Grad et al., 2016) | AZM (Lk et al., 2002) | ESCs (Grad et al., 2014) | N/A | N/A | |
| Prevalence of variant in dataset | 1 | 10.04%* | 0.11% | 5.25% | 1.47% | 0.11% |
| 2 | 1.14% | 1.24% | 1.69% | 0% | 0% | |
| 3 | 2.47% | 0.95% | 15.68%* | 1.04% | 0.76% | |
| 4 | 11.07%* | 1.23% | 0.41% | 6.56% | 8.20% | |
| 5 | 0.75% | 0.50% | 2.26% | 0.25% | 0% | |
| Phylogenetic D statistic for variant in dataset | 1 | −0.18 | 17.50 | −0.29 | N/A | N/A |
| 2 | −0.10 | 0.46 | −0.24 | N/A | N/A | |
| 3 | 0.05 | 0.30 | −0.20 | N/A | N/A | |
| 4 | −0.16 | 1.83 | 1.81 | N/A | N/A | |
| 5 | 0.83 | 1.12 | −0.15 | N/A | N/A | |
-
*Given the >10% prevalence of RplD G70D in datasets 1 and 4 and penA XXXIV in dataset 3, these variants were excluded from sampling simulations.
AZM, azithromycin; ESC, extended-spectrum cephalosporin; CRO-RS, ceftriaxone reduced susceptibility; CFX-R, cefixime resistance.
Table 3
Summary of the potential diagnostic escape variants assessed.
| Variant | Diagnostic assay | Documented association with diagnostic failure | Prevalence in dataset | ||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |||
| 16S rRNA C1209A (four alleles) | Aptima GC Combo | Yes (Guglielmino et al., 2019) | 0.11% | 0.09% | 0% | 0% | 0% |
| N. meningitidis-like porA | In-house (Whiley et al., 2004; Whiley et al., 2005) | Yes (Whiley et al., 2011; Golparian et al., 2012) | 0.11% | 0.05% | 0% | 0% | 0% |
| cppB deletion | In-house (Diemert et al., 2002; Van Dyck et al., 2001) | Yes (Bruisten et al., 2004) | 1.12% | 0.05% | 0.47% | 0% | 7.29% |
| DR-9A G168A | Roche COBAS 4800 CT/NG | No | 0% | 0.09% | 0% | 0% | 0% |
Table 4
Reference information for the genetic variants assessed.
| Variant | Reference accession | Coordinates of genetic locus in reference entry | Position of mutation in reference locus |
|---|---|---|---|
| RplD G70D | NC_011035.1 | 2033052–2033672 | amino acid 70 |
| 23S rRNA C2611T | NC_011035.1 | 1263408–1266305 | nucleotide 2603 |
| penA XXXIV | NZ_LT906440.1 | 1588456–1590201 | N/A (assessed presence/absence of this allele) |
| 16S rRNA C1209A | NC_011035.1 | 1266903–1268450 | nucleotide 1192 |
| N. meningitidis-like porA | NC_011035.1 | 735796–737125 | N/A (assessed nucleotide similarity across the full locus with a threshold of ≤ 90%)* |
| cppB deletion | LT592149.1 | 2912–3553 | N/A (assessed presence/absence of full locus) |
| DR-9A G168A | NC_011035.1 | 530088–530277 | nucleotide 168 |
-
*Isolates with a porA pseudogene with ≤90% similarity to the NC_011035.1 porA pseudogene were called positive for N. meningitidis-like porA. Note that all such isolates were confirmed to have a porA pseudogene that was ≥92% similar to the N. meningitidis porA (GenBank Accession: GQ173789.1), while all other isolates had ≤89% similarity to the N. meningitidis porA.
Additional files
-
Supplementary file 1
Metadata and resistance variant profiles for isolates assessed in this study.
M, men; W, women; MSM, men who have sex with men; MSW, men who have sex with women; WSM, women who have sex with men; CFX-R, cefixime resistance; CRO-RS, ceftriaxone reduced susceptibility; AZM-R, azithromycin resistance.
- https://cdn.elifesciences.org/articles/56367/elife-56367-supp1-v1.xlsx
-
Supplementary file 2
Dataset bias and targeted sampling results.
(A) Demographic and geographic sampling biases in datasets 1–3. (B) Detection efficiency of random, demography-, niche-, and geography-aware sampling approaches for resistance variants. (C) Detection efficiency of random sampling, as well as preferential sampling of patients that had recently engaged in overseas sex or in sex work, for resistance variants in dataset 2. (D) Detection efficiency of random and phylogeny-aware sampling approaches for resistance variants. (E) Detection efficiency of random and phylogeny-aware sampling approaches for variants associated with diagnostic escape. (F) Detection efficiency of random and genomic background-aware sampling approaches for resistance variants.
- https://cdn.elifesciences.org/articles/56367/elife-56367-supp2-v1.docx
-
Transparent reporting form
- https://cdn.elifesciences.org/articles/56367/elife-56367-transrepform-v1.pdf
